Skip to content
preclinicalCognitive & Anxiety

Dynorphin

Also known as: Dynorphin A, Dynorphin B, Dyn A, Big Dynorphin

Dynorphin is an endogenous opioid peptide family derived from the prodynorphin precursor, with dynorphin A (17 amino acids) being the most potent member. Unlike endorphins (which activate mu-opioid receptors for pleasure/pain relief), dynorphins preferentially activate kappa-opioid receptors (KOR), producing dysphoria, aversion, and stress responses. This "anti-reward" system counterbalances dopamine-mediated pleasure, and dysregulated dynorphin/KOR signaling is implicated in depression, addiction, and chronic stress.

4 cited references·4 researched benefits

Quick Answer

Dynorphin is an endogenous opioid peptide that preferentially activates kappa-opioid receptors (KOR), producing effects opposite to endorphins: dysphoria, aversion, and stress-like responses rather than pleasure. This "anti-reward" system counterbalances dopaminergic pleasure circuits and is critical for stress adaptation. Dysregulated dynorphin signaling is implicated in depression, addiction relapse, and chronic pain. KOR antagonists are being developed as novel antidepressants and anti-addiction therapies.

Key Facts

Mechanism
Dynorphin A (Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln) binds KOR with high selectivity over mu and delta opioid receptors. KOR activation couples to Gi/Go proteins, inhibiting adenylyl cyclase, activating GIRK channels, and inhibiting voltage-gated calcium channels. In the nucleus accumbens, dynorphin release from medium spiny neurons reduces dopamine release from VTA terminals, producing the dysphoric "anti-reward" state. This serves as a homeostatic brake on excessive dopamine signaling. Stress activates corticotropin-releasing hormone (CRH) neurons that stimulate dynorphin release, creating a stress → dynorphin → dysphoria → drug-seeking cycle in addiction.
Research Status
preclinical
Half-Life
~5–10 minutes
Molecular Formula
C₉₉H₁₅₅N₃₁O₂₃
Primary Use
Cognitive & Anxiety
Table of Contents

Benefits

  • Addiction research — understanding dynorphin/KOR as the "anti-reward" system is foundational to addiction neurobiology and treatment developmentstrong
  • KOR antagonist drug target — KOR blockade reduces stress-induced relapse, depression-like behavior, and dysphoria in preclinical modelsstrong
  • Pain modulation — dynorphin participates in spinal cord pain processing and may have analgesic or pronociceptive effects depending on contextmoderate
  • Stress adaptation — appropriate dynorphin signaling helps calibrate responses to stress and prevent excessive reward-seekingmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Research use onlyN/AN/ADynorphin is not used therapeutically. Research focuses on KOR antagonists (e.g., aticaprant, navacaprant) as antidepressants and anti-addiction agents, and KOR agonists for non-addictive analgesia. Salvinorin A (from Salvia divinorum) is a natural KOR agonist used in research.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Dysphoria — KOR activation produces aversive emotional states, opposite to the euphoria of mu-opioid activationcommon
  • Sedation — dynorphin/KOR activation produces sedation distinct from the drowsiness of mu-opioid agonistscommon
  • Psychotomimetic effects — high-dose KOR agonists can produce hallucinations and dissociation (e.g., salvinorin A)serious
  • Diuresis — KOR activation inhibits vasopressin release, increasing urine outputcommon

Frequently Asked Questions

Why is dynorphin called the "anti-reward" peptide?
In the brain's reward circuit, dopamine produces pleasure and reinforces rewarding behaviors. Dynorphin acts as a counterbalance: when released in the nucleus accumbens, it activates KOR on dopamine terminals, inhibiting dopamine release. This produces a dysphoric, aversive state that opposes reward. This system normally prevents excessive reward-seeking, but in addiction, chronic drug use elevates dynorphin levels, creating a persistent negative emotional state (withdrawal dysphoria) that drives relapse to restore dopamine balance.
How are KOR antagonists being developed as antidepressants?
Elevated dynorphin/KOR signaling is observed in depression and chronic stress, contributing to anhedonia (inability to feel pleasure) and negative mood. KOR antagonists block this excessive dynorphin signaling, restoring dopaminergic tone and mood. Aticaprant (JNJ-67953964, Janssen) is in phase 3 clinical trials as an adjunctive treatment for major depression, and navacaprant is in phase 2. These represent a novel mechanism distinct from SSRIs, SNRIs, and ketamine-based approaches.
What is the connection between dynorphin and the "runner's high"?
Prolonged exercise activates both endorphin (mu-opioid) and endocannabinoid systems, producing euphoria. However, exercise also elevates dynorphin, which may explain why the runner's high is not simply euphoric but includes a complex mix of mood states. Some researchers suggest that the dynorphin elevation during intense exercise contributes to the subsequent "afterglow" — the post-exercise sense of calm and accomplishment may partly result from dynorphin's aversive effects ceasing, creating a relative positive mood shift.
Does dynorphin play a role in chronic pain?
Dynorphin has a complex role in pain. In the spinal cord, dynorphin is upregulated in chronic pain states and can paradoxically promote pain through non-opioid mechanisms (NMDA receptor activation, neuroinflammation). Spinal dynorphin elevation is associated with pathological pain sensitization in neuropathic and inflammatory pain models. This pronociceptive role is distinct from its antinociceptive effects at supraspinal KOR sites. Understanding this duality is important for developing KOR-targeted pain therapies.

References

  1. 1
    Dynorphin, stress, and depression: role of the kappa opioid receptor system(2010)PubMed ↗
  2. 2
    The dark side of the opioid system: role of dynorphin/KOR in drug addiction and mood disorders(2012)PubMed ↗
  3. 3
    Kappa opioid receptor antagonists as potential antidepressants: a systematic review(2020)PubMed ↗
  4. 4
    Prodynorphin-derived peptides: complex roles in pain, stress, and reward(2016)PubMed ↗

Latest Research

Last updated: 2026-02-19